Advertisement

Topics

Search Results for "Sunitinib"

12:32 EDT 19th October 2017 | BioPortfolio

Matching Channels

None

Matching News

Individualized Sunitinib Dosing Improves Response, Survival in RCC

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

Global and Chinese Sunitinib base Industry, 2017 Market Research Report [Report Updated: 07042017] Prices from USD $3000

The 'Global and Chinese Sunitinib base Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Sunitinib base industry with a focus on the Chi...

Argos Presents Positive Interim Data for Rocapuldencel-T at ESMO

NewsA total of 462 patients with previously untreated advanced or metastatic renal cell carcinoma were enrolled in the ADAPT trial and randomized 2:1 between combination treatment with Rocapuldencel-T...

Sunitinib Malate Market: By Disease Pancreatic Neuroendocrine Tumors Kidney Cancer By Region Europe, North America, AsiaPacific Rest of the World RoWForecast 20162021 [Updated: 13092016] Prices from USD $5250

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a smallmolecule medicine which has to be administered orally and has been proven to be effective in blocki...

CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma

Dr Escudier presents in a press conference at the ESMO 2017 Congress data from the CheckMate 214 trial looking into the efficacy and safety of nivolumab ipilimumab versus sunitinib for treatment-na...

Bristol-Myers Stops Late-Stage Kidney Cancer Trial Early Following Successful Results

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanc...

Bristol-Myers Squibb’s Kidney Cancer Drug Met Co-Primary Endpoint in Late-Stage Trial

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination wi...

ESMO 2017: Nivolumab-Ipilimumab Combination Reduced Risk of Death in RCC by 37%

CheckMate-214 results presented at the European Society of Medical Oncology meeting show improved overall survival in patients with renal cell carcinoma treated with the nivolumab-ipilimumab combinati...

Matching PubMed Articles

Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.

Renal cell carcinoma (RCC) represents 2%-3% of all cancers of the Western countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and VEGF receptors, is the first-l...

Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.

Coadministration of diclofenac and sunitinib, tyrosine kinase inhibitor, led to sex-divergent pharmacokinetic drug-drug interaction outcomes. Male and female mice were administered 60 mg/kg PO suniti...

In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study.

Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have n...

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.

In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosin...

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

The identification of new therapeutic strategies is urgently needed for the management of patients affected by anaplastic thyroid cancer (ATC) due to their short survival and poor prognosis. Aim of th...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement